Your browser doesn't support javascript.
loading
Metronidazole stewardship initiative at Christchurch hospitals-achievable with immediate benefits.
Gardiner, Sharon J; Metcalf, Sarah Cl; Chin, Paul Kl; Doogue, Matthew P; Dalton, Simon C; Chambers, Stephen T.
Afiliação
  • Gardiner SJ; Antimicrobial Stewardship Pharmacist, Departments of Infectious Diseases, Clinical Pharmacology and Pharmacy, Canterbury District Health Board, Christchurch.
  • Metcalf SC; Infectious Diseases Physician, Department of Infectious Diseases, Canterbury District Health Board, Christchurch.
  • Chin PK; Clinical Pharmacologist and Senior Lecturer, Department of Clinical Pharmacology, Canterbury District Health Board, Christchurch; Department of Medicine, University of Otago, Christchurch.
  • Doogue MP; Clinical Pharmacologist and Associate Professor, Department of Clinical Pharmacology, Canterbury District Health Board, Christchurch; Department of Medicine, University of Otago, Christchurch.
  • Dalton SC; Infectious Diseases Physician, Department of Infectious Diseases, Canterbury District Health Board, Christchurch.
  • Chambers ST; Infectious Diseases Physician and Professor, Department of Infectious Diseases, Canterbury District Health Board, Christchurch; Department of Pathology, Canterbury District Health Board, Christchurch.
N Z Med J ; 131(1473): 53-58, 2018 04 13.
Article em En | MEDLINE | ID: mdl-29649197
AIMS: To evaluate an antimicrobial stewardship (AMS) initiative to change hospital prescribing practice for metronidazole. METHODS: In October 2015, the Canterbury District Health Board (CDHB) AMS committee changed advice for metronidazole to promote two times daily dosing for most indications, prioritisation of the oral route and avoidance of double anaerobic cover. Adoption of the initiative was facilitated via change in prescribing guidelines, education and ongoing pharmacy support. Usage and expenditure on metronidazole for adult inpatients were compared for the five years pre- and two years post-change. Other district health boards (DHBs) were surveyed to determine their dosing recommendation for metronidazole IV. RESULTS: Mean annual metronidazole IV use, as defined daily doses per 1,000 occupied bed days, decreased by 43% post-initiative. Use of non-IV (oral or rectal) formulations increased by 104%. Total savings associated with the initiative were approximately $33,400 in drug costs plus $78,200 per annum in IV giving sets and post-dose flushes. Twelve of 20 (60%) DHBs (including CDHB) endorse twice daily IV dosing. CONCLUSIONS: In addition to financial savings, reduction in IV doses has potential benefits, including avoidance of IV catheter-associated complications such as bloodstream infections. Approaches to metronidazole dosing vary across DHBs and could benefit from national coordination.
Assuntos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Custos de Medicamentos / Uso de Medicamentos / Gestão de Antimicrobianos / Hospitais Públicos / Metronidazol Tipo de estudo: Guideline / Qualitative_research Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Custos de Medicamentos / Uso de Medicamentos / Gestão de Antimicrobianos / Hospitais Públicos / Metronidazol Tipo de estudo: Guideline / Qualitative_research Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article